Dr. Reddy's Laboratories Ltd (NYSE:RDY) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY - Get Free Report) have been given an average rating of "Moderate Buy" by the five brokerages that are presently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $16.95.

Several equities analysts have recently issued reports on the company. Hsbc Global Res raised Dr. Reddy's Laboratories from a "hold" rating to a "strong-buy" rating in a research report on Thursday, June 5th. Zacks Research raised Dr. Reddy's Laboratories from a "strong sell" rating to a "hold" rating in a research report on Friday. HSBC raised Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating and lifted their price target for the stock from $14.44 to $16.90 in a research report on Thursday, June 5th. Finally, Wall Street Zen raised Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th.

Dr. Reddy's Laboratories Price Performance

Shares of Dr. Reddy's Laboratories stock opened at $14.26 on Tuesday. The company has a quick ratio of 1.36, a current ratio of 1.89 and a debt-to-equity ratio of 0.01. The company has a market cap of $11.90 billion, a PE ratio of 21.60, a P/E/G ratio of 5.72 and a beta of 0.29. The business has a 50 day moving average of $14.73 and a 200 day moving average of $14.02. Dr. Reddy's Laboratories has a 52 week low of $12.26 and a 52 week high of $16.85.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The company reported $0.20 EPS for the quarter, beating analysts' consensus estimates of $0.18 by $0.02. The company had revenue of $988.82 million during the quarter, compared to the consensus estimate of $88.27 billion. Dr. Reddy's Laboratories had a return on equity of 17.25% and a net margin of 16.99%. As a group, equities research analysts forecast that Dr. Reddy's Laboratories will post 0.8 earnings per share for the current year.

Institutional Trading of Dr. Reddy's Laboratories

A number of large investors have recently added to or reduced their stakes in the company. Robeco Institutional Asset Management B.V. increased its stake in Dr. Reddy's Laboratories by 13.6% in the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 12,163,428 shares of the company's stock worth $182,816,000 after acquiring an additional 1,452,192 shares during the last quarter. Royal Bank of Canada boosted its holdings in shares of Dr. Reddy's Laboratories by 403.1% in the 4th quarter. Royal Bank of Canada now owns 10,037,246 shares of the company's stock worth $158,489,000 after purchasing an additional 8,042,163 shares during the period. Aikya Investment Management Ltd boosted its holdings in shares of Dr. Reddy's Laboratories by 2.5% in the 2nd quarter. Aikya Investment Management Ltd now owns 6,354,979 shares of the company's stock worth $95,515,000 after purchasing an additional 154,604 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Dr. Reddy's Laboratories by 157.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 5,910,786 shares of the company's stock worth $88,839,000 after purchasing an additional 3,617,435 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Dr. Reddy's Laboratories by 405.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 5,361,013 shares of the company's stock worth $84,643,000 after purchasing an additional 4,301,212 shares during the period. Institutional investors own 3.85% of the company's stock.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.